Le Lézard
Classified in: Health
Subjects: SBS, MAT

Canna Hemptm Poised to Be A Front-Runner In The World Of CBD


FORT LAUDERDALE, Fla., March 20, 2020 /PRNewswire/ -- U.S. based brand, Canna Hemptm has been setting the standard for high-quality CBD wellness products since its inception in 2016. Canna Hemptm stands out in a saturated space due to its emphasis on third-party testing on all of its CBD, and for the cutting-edge combinations of CBD with other natural ingredients to produce a diverse catalog of products that really work.

What started as a home-based enterprise for founder Chris Rebentisch has grown to one of the largest and most successful CBD companies in the western United States. Rebentisch says his passion for creating organic and plant-based alternatives to pharmaceuticals comes from his first-hand experience. "The difference between our products and other products," says Rebentisch, "is that once customers try our products, they don't go back to what they were using before." And Canna Hemptm's rate of customer retention is no small feat.

As a burgeoning industry, CBD has experienced a lot of inconsistencies concerning the quality of products on the market. Whether it's a difference in dosage, content, or composition of ingredients, Canna Hemptm outperforms its competition across the board.

From its state-of-the-art facility, Canna Hemptm produces a variety of product lines, which include topical, creams, balms, ointments, tinctures, capsules, elixirs, and more. All of the CBD is supplied by its certified growers in Colorado, and Nevada, where Canna Hemptm is based.

Besides providing relief across a broad spectrum of medicinal conditions, Canna Hemptm says its mission is "to provide a safe, high-quality, non-psychoactive cannabis experience based on the latest science, and to cultivate community through education." This means that all of Canna Hemptm's products are designed to have all the benefits that come from cannabis, but with none of the "high."

For this reason, Canna Hemptm has been reaching a unique market in the realm of CBD, modern athletes. The company's specialty line, Canna Hemptm X, provides natural wellness products with topicals and elixirs to enable athletes and workout enthusiasts achieve their workout goals.

Canna Hemptm's range of diversity in the products it manufactures, and ultra-consistent quality in the sourcing of its ingredients, makes this publicly-traded company bound for even more success as they take their next steps towards national and international expansion in 2020.

Please direct inquiries to:
Vincent Isom (954) 399-2207
[email protected]

SOURCE Canna Hemp


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: